Novartis India Limited operates as a healthcare company in India. It offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands; and neurosciences products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.
Stock data | 2023 | Change |
---|---|---|
Price | $13.33 | N/A |
Market Cap | $329.12M | N/A |
Shares Outstanding | 24.69M | 0.00% |
Employees | 67.00 | N/A |
Shareholder Equity | 7.76B | 12.14% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.32 | N/A |
P/S Ratio | 7.48 | N/A |
P/B Ratio | 0.04 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0016 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $44.01M | N/A |
Earnings | $12.32M | N/A |
EPS | 41.86 | N/A |
Earnings Yield | 3.14 | N/A |
Gross Margin | 0.4456 | N/A |
Operating Margin | 0.1638 | N/A |
Net income margin | 0.28 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $117.19M | N/A |
Total Debt | $2.56M | N/A |
Cash on Hand | $66.10M | N/A |
Debt to Equity | 0.0032 | -30.48% |
Cash to Debt | $25.77 | 19.87% |
Current Ratio | $4.25 | 29.68% |